• If you are trying to figure out whether Guardian Pharmacy Services at around US$36.95 is still good value or starting to look stretched, the recent share price moves give you a lot to work with.
• The stock has had a mixed short term, with a 9.1% loss over the last week, an 8.4% gain over the last month, and returns of 25.1% year to date and 53.3% over the last year.
• Recent coverage has focused on Guardian Pharmacy Services as part of broader healthcare and services discussions, which has helped bring the stock onto more investors' radar. This mix of attention and price volatility is prompting closer scrutiny of what a fair price might look like.
• Simply Wall St currently gives Guardian Pharmacy Services a 1 out of 6 valuation score, and the sections that follow will compare common valuation methods and point to a more complete way to think about value that will be covered at the end of the article.

Guardian Pharmacy Services scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Guardian Pharmacy Services Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company could be worth by projecting its future cash flows and discounting them back to today using a required rate of return. It is essentially asking what all those future dollars are worth in present terms.

For Guardian Pharmacy Services, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections rather than earnings. The latest twelve month Free Cash Flow is about $80.62 million. Analyst inputs run through 2027, with Simply Wall St extrapolating further out, including a projected Free Cash Flow of $105.25 million in 2035, all in $ and all below the 1b mark.

Pulling these projections together, the DCF model arrives at an estimated intrinsic value of about $34.43 per share, compared with the current share price of around $36.95. That implies the stock is about 7.3% overvalued on this DCF view, which is a relatively small gap and within a range where market expectations and model assumptions can easily differ.

Result: ABOUT RIGHT

Guardian Pharmacy Services is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Guardian Pharmacy Services Price vs Earnings

For profitable companies, the P/E ratio is a useful shorthand for how much you are paying for each dollar of earnings. It ties the share price directly to the bottom line, which is often what ultimately matters for long term shareholders.

What counts as a “normal” P/E largely reflects what the market expects from a company and how risky those earnings are. Higher expected earnings growth or lower perceived risk can support a higher P/E, while slower expected growth or higher risk usually points to a lower one.

Guardian Pharmacy Services currently trades on a P/E of 47.54x. That is close to the peer average of 48.79x and well above the broader Healthcare industry average of 23.04x. Simply Wall St also calculates a “Fair Ratio” of 22.43x for Guardian Pharmacy Services, which is its proprietary view of what the P/E could be given factors such as earnings growth, industry, profit margins, market cap and company specific risks.

This Fair Ratio aims to be more tailored than a simple comparison with peers or the sector, because it adjusts for company characteristics rather than relying only on broad group averages. Set against the current 47.54x P/E, the Fair Ratio of 22.43x suggests the shares are trading at a richer multiple than those fundamentals imply.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Guardian Pharmacy Services Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St help you write the story behind your numbers by linking your view of Guardian Pharmacy Services, such as expectations for revenue, earnings and margins, to a financial forecast and a fair value that you can easily compare with the current price. All of this sits within the Community page where millions of investors share views, and these Narratives refresh when new information like news or earnings arrives. You can see, for example, one investor anchoring on the analysts’ consensus fair value of US$34.00, while another builds a more cautious or more optimistic path around the same earnings range of US$67.7m to US$102.1m. Each then decides whether the current price looks attractive or not based on their own Fair Value versus Price gap.

Do you think there's more to the story for Guardian Pharmacy Services? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.